Navigation Links
A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
Date:9/19/2012

esponder patients chronically infected with HCV genotype 1a.

Additional information about this study will be posted on http://www.clinicaltrials.gov

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir (TMC435), a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Research & Development Ireland.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia. and today Medivir has a broad product portfolio with prescription pharmaceuticals in the Nordics.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, is launched in collaboration with GlaxoSmithKline to be sold OTC under the brand name ZoviDuo in Europe, Japan and Russia.

Medivir's IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Direct: +46-8-440-6550 or:
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
4. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
5. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
6. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
7. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
9. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
10. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Amici Procurement ... procurement company Amici Procurement has chosen Microsoft Cloud Solution ... move to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) ... to medium-sized companies in the bio-tech sector with a ... the purchasing cycle to help them obtain best value. ...
(Date:7/1/2015)... BURLINGTON, Mass. , July 1, 2015 /PRNewswire/ ... three most frequently cited advantages of Otezla are ... favorable safety profile, as reported by surveyed rheumatologists. ... and launched for the treatment of active psoriatic ... . The current standard of care includes conventional ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, ... has earned three Gold, three Silver, and three Bronze ... gala held in Chicago this ... the premier business awards program in the U.S. ... our company,s strength in developing leaders, cultivating talent, creating ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... July 9 Human Genome Sciences, Inc. (Nasdaq: ... New England Journal of Medicine of the ... life-saving potential of the Company,s human monoclonal antibody drug raxibacumab ... which supported the use of raxibacumab in the event of ...
... gene that is essential for embryonic stem cells to ... may lead to a greater understanding of how cells ... efficiently reprogram mature cells back into the pluripotent state, ... crucial to a range of potential clinical treatments. ...
... July 8 Intellikine, Inc., a leader in the ... of cancer, inflammation and autoimmune diseases, announced today that ... Novartis Bioventures Ltd. led the financing in which ... FinTech Global Capital participated. Markus Goebel, M.D., Ph.D., ...
Cached Biology Technology:Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 3Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 4Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax 5Stem cells' 'suspended' state preserved by key step, scientists report 2Stem cells' 'suspended' state preserved by key step, scientists report 3Intellikine Completes $51 Million Financing 2
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... Orangutans threatened with extinction could be brought back from ... Technology (QUT) statistician. Professor Kerrie Mengersen, from the ... to guide efforts for saving the Indonesian primate whose ... said the study had found a quarter of villagers ...
... Ore. An international group of scientists from the ... collaborating on a fascinating new climate modeling initiative ... create a network of digital power that surpasses that ... initial effort in 2003 and its "climateprediction.net" project has ...
... and neck cancer who have never smoked have much better ... of smoking, new research from UC Davis Cancer Center ... colleagues in the UC Davis radiation oncology and otolaryngology departments ... differences based on smoking history in patients with head and ...
Cached Biology News:Orangutans count on stats for survival 2OSU, Oxford, others launch citizen scientist climate modeling initiative 2OSU, Oxford, others launch citizen scientist climate modeling initiative 3Never-smokers fare far better than smokers after radiation therapy for head and neck cancer 2
ANTI CORTIS BIN GLOB...
... A.P. Johnstone and M.W. ... book describes step-by-step methods ... immunologically relevant molecules, the ... highly specific analytical probes ...
Request Info...
LabFax: Immunochemistry...
Biology Products: